The HIV diagnostics test market is estimated to be valued at USD 4.44 billion in 2024 and with a CAGR of 9.2% over the forecast period 2024 - 2031. Factors such as the high prevalence of HIV worldwide and growing awareness among people are expected to drive the market. Furthermore, technological advancements in HIV diagnostic tests are making them more affordable and accessible to many.
Market Dynamics:
Increasing HIV Prevalence: HIV continues to be a major public health issue. This growing disease burden has increased the demand for efficient and early detection of HIV. Both private organizations and governments are putting efforts towards creating awareness about HIV testing and prevention. Campaigns emphasize on the importance of regular screening, especially among high-risk groups. This has motivated more people to opt for diagnostic tests and seek timely treatment. The support of advocacy groups has further widened the reach of such programs.
Increasing Prevalence of HIV Globally
One of the major drivers for the HIV diagnostics test market is the increasing prevalence of HIV infections worldwide. Sub-Saharan Africa remains most severely affected, with nearly 1 in every 25 adults living with HIV in this region. The rising cases of HIV infections is driving the demand for advanced and reliable HIV diagnostic tests for detection and management of the virus.
Growing Adoption of Point-of-Care HIV Tests
Point-of-care (POC) HIV tests that can provide results within 20-30 minutes have gained immense popularity as they enable testing and receiving results at the location of patient care. The ease of use and convenience of POC HIV tests compared to traditional lab-based tests has boosted their adoption rate globally. Healthcare providers are also advocating the use of POC tests as they allow integration of HIV screening into medical settings. The emergence of self-screening HIV tests is further expected to drive the demand.
Limited Healthcare Infrastructure and Low Testing Rates in Developing Regions
Despite increased awareness, many developing nations still have low HIV testing rates due to various deficiencies in their healthcare systems. Factors such as lack of diagnostic centers, shortage of trained professionals, and inadequate funding for HIV programs hamper widespread adoption of diagnostics in these regions.
High Cost of Advanced HIV Diagnostic Technologies
Newer HIV diagnostic technologies offer higher reliability and faster results compared to conventional tests. However, their production and deployment costs are significantly high. This adversely impacts their affordability and widespread adoption especially in low and middle-income countries. The need for continuous investment in research and development to develop low-cost testing solutions also burdens manufacturers. This cost factor poses challenges to market growth.
Scope for Improving Testing Rates in Under-Screened Groups
Certain demographic groups like adolescents, pregnant women and key populations continue to exhibit low HIV testing participation globally. The market sees opportunities to collaborate with health ministries to devise innovative and targeted programs to boost case detection among under-screened groups.
Demand for Integrated Solution Products
Players are exploring the potential to develop integrated devices that combine HIV diagnostic capabilities along with screening for other major health parameters like tuberculosis, hepatitis, and sexually transmitted infections. The demand for multi-disease testing platforms from healthcare facilities provides ample opportunities in this market.
Link: https://www.coherentmarketinsights.com/market-insight/hiv-diagnostics-market-422
Key Development
- In April 2023, Biosynex SA, a leading France-based provider of rapid test solutions, announced the successful completion of its acquisition of Chembio Diagnostics, Inc., a prominent point-of-care diagnostics firm specializing in infectious diseases. Chembio boasts multiple FDA-approved products, including 510k, PMA, and CLIA waived products. Additionally, its recognized presence in the rapid HIV test market with WHO-prequalified products presents Biosynex SA with expanded international commercial opportunities.
- In March 2023, Trinity Biotech plc, a key developer and manufacturer of diagnostic products for point-of-care and clinical laboratory settings, commended the Kenyan Ministry of Health's adoption of a new HIV fast testing algorithm. Trinity Biotech's TrinScreen HIV has been designated as the screening test, aligning with World Health Organization recommendations.
- In February 2023, a collaborative effort involving the Kyrgyz Ministry of Health, Neman-Pharm, a retail pharmacy chain, and the U.S. Agency for International Development (USAID) was announced to provide free HIV self-testing kits. These kits will be available at 32 pharmacies across Bishkek, Osh, and the Chui and Osh regions of the Kyrgyz Republic. This initiative aims to improve access to HIV testing, particularly for vulnerable and hard-to-reach populations.
- In July 2022, MedAccess, a social enterprise dedicated to advancing health in low- and middle-income nations, along with the Clinton Health Access Initiative (CHAI), a global health organization, and Wondfo, a rapidly growing biotechnology company, unveiled a partnership to offer Wondfo's HIV self-test for USD 1. This price represents a reduction of over 30% compared to the current lowest-priced WHO-prequalified test and is 50% lower than the most widely used test. Consequently, Wondfo's HIV self-test becomes the most affordable WHO-prequalified self-test on the market.
Key Players: Abbott, Bio-Rad Laboratories Inc., Hologic Inc., Siemens Healthineers, F. Hoffmann-La Roche Ltd., Beckman Coulter Inc., OraSure Technologies Inc., Becton Dickinson and Company, Merck KGaA, Biosynex SA., Zyomyx Incorporation, Bristol –Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.
